Search Results - "McNeil, Catriona M."

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study by Robert, Caroline, Prof, Ribas, Antoni, Prof, Schachter, Jacob, Prof, Arance, Ana, MD, Grob, Jean-Jacques, Prof, Mortier, Laurent, Prof, Daud, Adil, Prof, Carlino, Matteo S, MB, McNeil, Catriona M, MD, Lotem, Michal, Prof, Larkin, James M G, Prof, Lorigan, Paul, Prof, Neyns, Bart, Prof, Blank, Christian U, Prof, Petrella, Teresa M, MD, Hamid, Omid, MD, Su, Shu-Chih, PhD, Krepler, Clemens, MD, Ibrahim, Nageatte, MD, Long, Georgina V, Prof

“…SummaryBackgroundPembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a…”
Get full text

The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome by Ricciardelli, Carmela, Bianco-Miotto, Tina, Jindal, Shalini, Butler, Lisa M, Leung, Samuel, McNeil, Catriona M, O'Toole, Sandra A, Ebrahimie, Esmaeil, Millar, Ewan K A, Sakko, Andrew J, Ruiz, Alexandra I, Vowler, Sarah L, Huntsman, David G, Birrell, Stephen N, Sutherland, Robert L, Palmieri, Carlo, Hickey, Theresa E, Tilley, Wayne D

“…Consensus is lacking regarding the androgen receptor (AR) as a prognostic marker in breast cancer. The objectives of this study were to comprehensively review…”
Get full text

Prediction of Local Recurrence, Distant Metastases, and Death After Breast-Conserving Therapy in Early-Stage Invasive Breast Cancer Using a Five-Biomarker Panel by MILLAR, Ewan K. A, GRAHAM, Peter H, NASSER, Elias, KEARSLEY, John H, DELANEY, Geoff, PAPADATOS, George, FOX, Christopher, SUTHERLAND, Robert L, O'TOOLE, Sandra A, MCNEIL, Catriona M, BROWNE, Lois, MOREY, Adrienne L, EGGLETON, Sarah, BERETOV, Julia, THEOCHAROUS, Constantine, CAPP, Anne

“…To determine the clinical utility of intrinsic molecular phenotype after breast-conserving therapy (BCT) with lumpectomy and whole-breast irradiation with or…”
Get full text

Cytoplasmic Localization of β-Catenin is a Marker of Poor Outcome in Breast Cancer Patients by LOPEZ-KNOWLES, Elena, ZARDAWI, Sarah J, MCNEIL, Catriona M, MILLAR, Ewan K. A, CREA, Paul, MUSGROVE, Elizabeth A, SUTHERLAND, Robert L, O'TOOLE, Sandra A

“…β-catenin is involved in cell adhesion through catenin-cadherin complexes and as a transcriptional regulator in the Wnt signaling pathway. Its deregulation is…”
Get full text

Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E by Butt, Alison J, McNeil, Catriona M, Musgrove, Elizabeth A, Sutherland, Robert L

“…Antioestrogen therapy is a highly effective treatment for patients with oestrogen-receptor (ER)-positive breast cancer, emphasising the central role of…”
Get full text

Coronavirus Farewell by McNeil, Catriona M

Get full text

A Cup of Coffee by McNeil, Catriona M

“…The secretary looks upset as she types a letter about a patient. “I just wish I could just write a different ending to her story,” she explains. We recognize…”
Get full text

Grace and Forgiveness by McNeil, Catriona M

Get full text

Banter by McNeil, Catriona M

Get full text

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma by Robert, Caroline, Long, Georgina V, Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Rutkowski, Piotr, Hassel, Jessica C, McNeil, Catriona M, Kalinka, Ewa Anna, Lebbé, Céleste, Charles, Julie, Hernberg, Micaela M, Savage, Kerry J, Chiarion-Sileni, Vanna, Mihalcioiu, Catalin, Mauch, Cornelia, Arance, Ana, Cognetti, Francesco, Ny, Lars, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Zoco, Jesús, Re, Sandra, Ascierto, Paolo A, Atkinson, Victoria

“…The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated wild-type advanced melanoma…”
Get full text

What Have We Got to Lose? by McNeil, Catriona M

Get full text

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial by Long, Georgina V, Atkinson, Victoria, Cebon, Jonathan S, Jameson, Michael B, Fitzharris, Bernie M, McNeil, Catriona M, Hill, Andrew G, Ribas, Antoni, Atkins, Michael B, Thompson, John A, Hwu, Wen-Jen, Hodi, F Stephen, Menzies, Alexander M, Guminski, Alexander D, Kefford, Richard, Kong, Benjamin Y, Tamjid, Babak, Srivastava, Archana, Lomax, Anna J, Islam, Mohammed, Shu, Xinxin, Ebbinghaus, Scot, Ibrahim, Nageatte, Carlino, Matteo S

“…Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose…”
Get full text

Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome by Beckers, Rhiannon K, Selinger, Christina I, Vilain, Ricardo, Madore, Jason, Wilmott, James S, Harvey, Kate, Holliday, Anne, Cooper, Caroline L, Robbins, Elizabeth, Gillett, David, Kennedy, Catherine W, Gluch, Laurence, Carmalt, Hugh, Mak, Cindy, Warrier, Sanjay, Gee, Harriet E, Chan, Charles, McLean, Anna, Walker, Emily, McNeil, Catriona M, Beith, Jane M, Swarbrick, Alexander, Scolyer, Richard A, O'Toole, Sandra A

“…Aims Triple‐negative breast cancer (TNBC) patients generally have a poor outcome; there is a pressing need to identify more effective therapeutic strategies…”
Get full text

PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality by López‐Knowles, Elena, O'Toole, Sandra A., McNeil, Catriona M., Millar, Ewan K.A., Qiu, Min R., Crea, Paul, Daly, Roger J., Musgrove, Elizabeth A., Sutherland, Robert L.

“…Breast cancer is a common malignancy with current biological therapies tailored to steroid hormone (ER, PR) and HER2 receptor status. Understanding the…”
Get full text

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B by Carlino, Matteo S, Menzies, Alexander M, Atkinson, Victoria, Cebon, Jonathan S, Jameson, Michael B, Fitzharris, Bernard M, McNeil, Catriona M, Hill, Andrew G, Ribas, Antoni, Atkins, Michael B, Thompson, John A, Hwu, Wen-Jen, Hodi, F Stephen, Guminski, Alexander D, Kefford, Richard, Wu, Haiyan, Ibrahim, Nageatte, Homet Moreno, Blanca, Long, Georgina V

“…Combination therapy with reduced-dose programmed death 1 inhibitor plus standard-dose cytotoxic T-lymphocyte-associated antigen 4 inhibitor demonstrated…”
Get full text

Bereaved and aggrieved in the age of social media by McNeil, Catriona M, Tattersall, Martin H N

“…Respected colleagues-doctors, nurses, allied health professionals-are now the subject of vile social media feeds and blogs, streams of expletives,…”
Get full text

Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy by Prasanna, Thiru, McNeil, Catriona M, Nielsen, Theresa, Parkin, David

“…We report a case of isolated immune-related pancreatic exocrine insufficiency in a patient treated with pembrolizumab for metastatic melanoma. This patient…”
Get full text

Our Faustian pact with the digital world by McNeil, Catriona M, Harnett, Paul R

“…[...]despite the impressive responses seen in clinical trials of novel targeted and immune therapeutics for diseases such as melanoma and non-small-cell lung…”
Get full text

Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery by Strach, Madeleine C., Prasanna, Thiru, Kirova, Youlia M., Alran, Severine, O’Toole, Sandra, Beith, Jane M., Poortmans, Philip, McNeil, Catriona M., Carroll, Susan

“…[Display omitted] Modern breast cancer care is a complex multidisciplinary undertaking in which the integrated function of multiple constituent parts is…”
Get full text

Misunderstandings, mandatory biopsies, and conflicts of interests in clinical trials: a coercive cocktail? by McNeil, Catriona M, Tattersall, Martin H N

“…Established dogma regarding restrictive trial eligibility criteria are being challenged.1 Moreover, as study designs become increasingly iterative and complex,…”
Get full text